Biological Times

Volume No. 5 | Issue No. 8 | Pages 13-14

Diabetes Mellitus: Pathophysiology, Clinical Manifestations, and Associated Complications

Aleeza Maqbool[1], Ayesha Sajjad[2], Hafiza Sehar Shakoor[3], Sadia Naz[4] and Rimsha Amjad[5]

1. BS Nursing, College of Nursing, Khawaja Muhammad Safdar Medical College, Sialkot, Pakistan
2. Department of Nutritional Sciences, Faculty of Medical Sciences, Government College University Faisalabad, Pakistan
3. Department of Physiology, Faculty of Life Sciences, Government College University Faisalabad, Pakistan
4. Institute of Biochemistry, Biotechnology and Bioinformatics, Department of Bioinformatics, The Islamia University of Bahawalpur, Pakistan
5. Department of Food Science and Human Nutrition, Faculty of Bio-Sciences, University of Veterinary and Animal Sciences, Lahore, Pakistan

*Corresponding Author: **aleeza1484@gmail.com**

ABSTRACT

Diabetes Mellitus (DM) is a chronic, progressive metabolic disorder that demands a multidisciplinary, patient-centered approach. The distinction between type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM), based on pathophysiology and therapeutic requirements, guides initial management, but both types share the common goal of maintaining glycemia as close to normal as safely possible while minimizing treatment burden and hypoglycemia risk. Advances in glucose monitoring technology, insulin delivery systems, and cardio-renal protective pharmacotherapy have transformed the therapeutic landscape. Nevertheless, the cornerstone of effective diabetes care remains early detection, structured education, lifestyle intervention, and systematic surveillance for complications. With appropriate management, individuals with diabetes can achieve near-normal life expectancy and quality of life, underscoring the importance of translating pathophysiologic understanding into practical, evidence-based clinical care.

Keywords: Diabetes Mellitus, Pathophysiology, Clinical Manifestations

To cite this article: Maqbool A, A Sajjad, HS Shakoor, S Naz & R Amjad. Diabetes Mellitus: Pathophysiology, Clinical Manifestations, and Associated Complications. Biological Times. 2026. August 5(8): 13-14.

Introduction

Diabetes Mellitus (DM) a heterogeneous group of metabolic disorders defined by persistent hyperglycemia resulting from absolute or relative deficiencies in insulin secretion, defects in insulin action, or a combination of both. The disease represents a major public health challenge worldwide, with prevalence continuing to rise due to population aging, urbanization, sedentary lifestyles, and increasing obesity rates [1]. According to current epidemiological data and clinical guidelines, DM is classified primarily into type 1 diabetes mellitus, type 2 diabetes mellitus, gestational diabetes mellitus, and other specific types, with Type 1 and Type 2 accounting for over 95% of all cases [2]. The clinical significance of DM extends beyond hyperglycemia itself, because chronic elevation of blood glucose leads to progressive damage of multiple organ systems, particularly the eyes, kidneys, nerves, heart, and peripheral vasculature. The long-term complications of diabetes are the primary determinants of morbidity, disability, and premature mortality in affected individuals, making early diagnosis, risk stratification, and comprehensive management central to modern medical practice [3].

Clinical Symptoms

The clinical presentation of diabetes mellitus centers on the classic triad of polyuria, polydipsia, and polyphagia with weight loss. Polyuria arises from osmotic diuresis when blood glucose exceeds the renal threshold and spills into the urine, carrying water with it. This leads to dehydration and compensatory polydipsia [4]. Additional common symptoms include fatigue, blurred vision due to osmotic swelling of the lens, dry mouth, and recurrent infections of the skin, urinary tract, and oral mucosa. Neurologic symptoms such as paresthesias or numbness in the feet and hands may indicate early diabetic peripheral neuropathy [12].

Epidemiology

In 2024, an estimated 11.11% of adults aged 20–79 years were living with diabetes, corresponding to 589 million people worldwide. If current trends continue, this figure is projected to rise to 12.96%, or 853 million adults, by 2050, representing a 46% increase in just 26 years. This growth is part of a longer trajectory. More than 90% of these cases are type 2 diabetes, driven primarily by urbanisation, ageing populations, physical inactivity, and rising obesity rates. Type 1 diabetes accounts for a smaller but significant burden [13]. New diagnoses in 2025 are estimated at 513,000, of which 219,000 are in children and youth. Mortality remains high, with 174,000 premature deaths per year. Demographic patterns show that prevalence peaks in the 75–79 age group and remains high in adults over 65. Males have a slightly higher prevalence than females. These data highlight that without urgent prevention and early detection efforts, diabetes will affect 1 in 8 adults by 2050 [5].

Pathophysiology of Type 1

Type 1 diabetes mellitus is a chronic autoimmune disease characterized by the selective destruction of pancreatic β-cells in the islets of Langerhans, leading to an absolute deficiency of insulin. Environmental triggers such as viral infections, notably enteroviruses like Coxsackie B4, dietary factors, and gut microbiome alterations are thought to initiate the autoimmune cascade in genetically susceptible individuals [6]. Upon exposure to these triggers, autoreactive CD4+ and CD8+ T-lymphocytes are activated against β-cell antigens. These activated T-cells infiltrate the pancreatic islets in a process known as insulitis, where CD8+ cytotoxic T-cells directly kill β-cells, while CD4+ helper T-cells and B-cells amplify the response by producing autoantibodies. The result is a progressive loss of β-cell mass; clinical hyperglycemia typically manifests only after >80–90% of β-cells have been destroyed [14]. Without insulin, peripheral tissues cannot take up glucose, causing hyperglycemia, polyuria, and polydipsia. Concurrently, uninhibited lipolysis and proteolysis occur, leading to ketogenesis. The accumulation of ketone bodies produces diabetic ketoacidosis (DKA), a life-threatening complication of absolute insulin deficiency. Thus, T1DM is defined by autoimmune-mediated β-cell failure, absolute insulin deficiency, and the downstream metabolic derangements of hyperglycemia and ketoacidosis [7].

Pathophysiology of Type 2

Type 2 diabetes mellitus is a complex, progressive metabolic disorder characterized by the dual defects of insulin resistance and relative insulin deficiency [8]. The core pathophysiology begins with insulin resistance, primarily in skeletal muscle, adipose tissue, and the liver [17,21]. In muscle, impaired insulin signaling reduces glucose uptake. In adipose tissue, resistance to insulin's antilipolytic action increases free fatty acid (FFA) release; and in the liver, resistance leads to unchecked gluconeogenesis and glycogenolysis, contributing to fasting hyperglycemia. Elevated FFAs also cause lipotoxicity, impairing insulin signaling further in a vicious cycle [9]. To compensate, pancreatic β-cells increase insulin secretion, resulting in hyperinsulinemia. Over time, chronic metabolic stress from glucotoxicity, lipotoxicity, oxidative stress, and inflammation induces β-cell dysfunction and apoptosis. This β-cell failure transforms compensated insulin resistance into overt hyperglycemia. Genetic predisposition interacts with environmental factors such as obesity, physical inactivity, and diet to drive these processes [18]. Unlike type 1 diabetes, type 2 diabetes mellitus does not involve autoimmune β-cell destruction, and ketoacidosis is uncommon because some insulin secretion is usually preserved. The net result is chronic hyperglycemia, which drives microvascular and macrovascular complications [10].

Management

The management of diabetes is lifelong and must be individualized to the patient's age, comorbidities, life expectancy, and preferences. For all

patients, medical nutrition therapy, regular physical activity, and diabetes self-management education form the foundation of care. Sleep-wake cycles and regular breakfast consumption also tend to have a positive impact on glucose management [16,19-20]. Nutritional recommendations emphasize carbohydrate counting, limitation of saturated fat and refined sugars, and achievement of a healthy body weight. Self-monitoring of blood glucose or use of continuous glucose monitoring systems enable patients to adjust therapy in real time [11,15].

Conclusion and Recommendations

In conclusion, Diabetes Mellitus is a complex, chronic metabolic disorder with far-reaching health consequences. Its rising prevalence globally makes it a priority for health systems, policymakers, and individuals. While there is currently no cure for most forms of diabetes, it can be effectively managed. From a public health perspective, diabetes imposes a substantial economic burden due to direct medical costs and indirect costs from disability and lost productivity. Health systems must prioritize integrated care models that link primary care with specialist services. Use of technology such as continuous glucose monitoring, insulin pumps, and telemedicine has improved outcomes but also highlights disparities in access. Health equity must be central to diabetes strategies to ensure that vulnerable populations are not left behind.

The evidence is clear that early diagnosis, individualized glycemic targets, comprehensive risk factor management, patient education, and prevention of complications lead to better outcomes and longer, healthier lives. Authorized guidelines from WHO and ADA emphasize that diabetes care must be patient-centered, evidence-based, and continuous. Future progress will depend on advances in precision medicine, technology, and public health interventions aimed at prevention. Ultimately, reducing the burden of diabetes requires coordinated action at the individual, community, and global levels to promote healthy lifestyles, ensure access to quality care, and support people living with this condition to thrive.

References

[1] American Diabetes Association. (2024). Standards of care in diabetes—2024. Diabetes Care, 47(Suppl. 1), S1–S321.

[2] Powers AC, Niswender KD, Evans-Molina C. Diabetes mellitus: diagnosis, classification, and pathophysiology. Diabetes. 2022;1000:415.

[3] ElSayed NA, et al. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes—2024. Diabetes Care. 2024;47(S1):S20-S42.

[4] Zelniker TA, et al. _SGLT2 inhibitors for prevention of kidney disease outcomes in patients with type 2 diabetes_. Lancet Diabetes Endocrinol. 2023;11(5):326-335.

[5] Davies MJ, et al. _Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by ADA and EASD_. Diabetes Care. 2022;45(11):2753-2786. Updated 2024.

[6] International Diabetes Federation. IDF Diabetes Atlas, 10th Edition. Brussels: IDF; 2021, updated 2023.

[7] Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. _Lancet_. 2014;383(9911):69-82.

[8] Katsarou A, Gudbjörnsdottir S, Rawshani A, et al. Type 1 diabetes mellitus. _Nat Rev Dis Primers_. 2017;3:17016.

[9] DiMeglio LA, Evans-Molina C, Oram RA. Type 1 diabetes. Lancet. 2018;391(10138):2487-2500.

[10] DeFronzo RA, Ferrannini E, Groop L, et al. Type 2 diabetes mellitus. _Nat Rev Dis Primers_. 2015;1:15019.

[11] Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. The Lancet. 2014 Mar 22;383(9922):1068-83.

[12] Afzal MA, Noor M, Shahzadi N, Saadat S, Chaudhry R, Zafar MN. Case study of a patient with decompensated type 2 diabetes mellitus and multiple comorbidities: implications for personalised care and disease modulation. Multidisciplinary Surgical Research Annals. 2025;3(3):744-56.

[13] Ashraf MA, Afzal MA, Ijaz M, Arshad A, Zafar MN, Ukkasha SM, Zahid I. Financial impact of nutrition on non-communicable diseases in hospital or other healthcare settings. Biological Times. 2025 Sep 4;4(9):20-1.

[14] Afzal MA, Ahmad T, Hameed H, Nadeem A, Rasool S, Malik S, Hassan M, Bibi F, Yawar A, Batool H, Saleem T, Smerat A. Pediatric obesity and metabolic syndrome: From pathogenesis to prevention and therapeutic management. Int J Drug Deliv Technol. 2026;16(63s):1566-1579.

[15] Fatima T, Qamar M, Afzal MA, Noor N, Tariq N, Yawar A, Abbasi AJ, Rahim F, Farooq MU, Noor M, Zahid I. The expanding role of artificial intelligence in health, life, and applied sciences: A multidisciplinary review. Social Science Review Archives. 2026 May 4;4(2):237-57.

[16] Shahzadi S, Sani KZ, Shabbir MH, Afzal MA, Mukhtar E, Ashraf S, Mahmood B, Zafar MN, Gull S, Khan SS, Rasheed MU. Chrononutrition and circadian rhythmicity: Exploring the temporal dynamics of nutrient intake in the regulation of glucose homeostasis and the therapeutic management of type 2 diabetes mellitus. Review Journal of Neurological & Medical Sciences Review. 2025;3(8):180-195.

[17] Afzal MA, Noor N, Sajjad I, Asghar M, Awais M, Aslam A, Mukhtar E, Afzal ZP, Tariq N, Batool H. Effects of meat consumption on human health: Nutritional benefits, associated risks, and implications for dietary recommendations. Continental Veterinary Journal, x. 2026.

[18] Afzal MA, Shahzadi N, Saadat S, Seemab R, Sajjad I, Tariq N, Ashraf SR, Tahir S, Kharl HA. CRISPR-Cas9 genome-editing technology: a transformative tool for curing human disorders. Journal of Medical & Health Sciences Review. 2025 Jul 29;2(3).

[19] Afzal MA, Habib A, Ahmed E, Bukhari I, Khan SS. The Importance of Breakfast: Nutritional Significance and Optimal Consumption Patterns. Biological Times. 2025 Jun 4;4(6):7-8.

[20] Afzal MA, Shahzadi N, Ahmed Z, Hyder A, Saleem, Zahra A, Zafar MN, Mukhtar E. Breakfast: The most important meal of the day or a myth? Biological Times. 2025;4(2):20-24.

[21] Khair UU, Tariq N, Izhar M, Kaleem A, Huda NU, Nadeem R, Iqbal MA, Rahim F, Danish M, Afzal MA. Nutritional and public health aspects of red and white meat: A veterinary perspective. In: Younus M, Abbas RZ, Akhtar T, editors. One Health and Global Health Security: Emerging Infectious Diseases, Antimicrobial Resistance and Public Health Challenges. Faisalabad (Pakistan): Unique Scientific Publishers; 2026. p. 217-223.